Description: Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.
Home Page: www.recbio.cn
No. 888 Yaocheng Avenue
Taizhou,
China
Phone:
86 523 8681 8860
Officers
| Name | Title |
|---|---|
| Dr. Yong Liu | CEO, GM & Chairman |
| Dr. Kunxue Hong | Chief Scientist & Non-Exec. Director |
| Dr. Jianping Chen | Vice GM & Exec. Director |
| Mr. Bu Li | Vice GM & Exec. Director |
| Ms. Qingqing Chen | Vice GM, CFO & secretary |
| Mr. Hongjun Zhou | Vice Gen. Mang. |
| Dr. Jianhui Zhang | Chief Medical Officer |
| Mr. Lei Zhou | Fin. controller |
| Ms. Jeanie Lau A.C.S. | Joint Company Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.7385 |
| Price-to-Sales TTM: | 1850.3584 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 478 |